Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27904262 | 0.86 | RAB9A (0.60) | RAB9APEPDALDH1A1SMN1; SMN2 | |
| SCHEMBL27922142 | 0.85 | RAB9A (0.44) | RAB9APEPDHCRTR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7771061 | 0.81 | RAB9A (0.53) | RAB9ADPP4ALDH1A1 | |
| SCHEMBL13604100 | 0.79 | RAB9A (0.38) | RAB9ADPP4PEPDHCRTR2 | |
| Hydrochloric Acid SCHEMBL3814969 | 0.78 | RAB9A (0.38) | RAB9ADPP4PEPDHCRTR2 | |
| SCHEMBL30975227 | 0.76 | DPP4 (0.48) | DPP4 | |
| SCHEMBL3810806 | 0.75 | DPP4 (0.48) | DPP4 | |
| SCHEMBL12469911 | 0.75 | RAB9A (0.47) | RAB9ADPP4SPHK2SPHK1SMN1; SMN2 | |
| SCHEMBL4845588 | 0.74 | DPP4 (0.44) | RAB9ADPP4PEPDALDH1A1SMN1; SMN2 | |
| SCHEMBL4615013 | 0.74 | DPP4 (0.44) | RAB9ADPP4PEPDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281352-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVES HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATES FOR PRODUCTION OF THE DERIVATIVES | MITSUI CHEMICALS, INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281352-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVES HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATES FOR PRODUCTION OF THE DERIVATIVES | MITSUI CHEMICALS, INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2008997-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVE HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATED FOR PRODUCTION OF THE DERIVATIVE | Mitsui Chemicals, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-2008997-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVE HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATED FOR PRODUCTION OF THE DERIVATIVE | Mitsui Chemicals, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281352-A1 | PROCESS FOR PRODUCTION OF ETHYLENEDIAMINE DERIVATIVES HAVING HALOGENATED CARBAMATE GROUP AND ACYL GROUP, AND INTERMEDIATES FOR PRODUCTION OF THE DERIVATIVES | ASNS, GLUL, NAAA | RAB9A 3162/4885DPP4 22/4885PEPD 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.